Efficacy of topical tacrolimus in atopic dermatitis
Keywords:
Atopic dermatitis, topical tacrolimusAbstract
Background Mainstay treatments for atopic dermatitis include cutaneous hydration, antihistamines and topical glucocorticoids. To avoid side effects associated with long term and higher potency topical corticosteroids, further topical immunosuppressive agents should be tried. Topical tacrolimus has been extensively studied and shows promise in treatment of inflammatory skin diseases such as atopic dermatitis.Objective To determine the safety and efficacy of tacrolimus in atopic dermatitis.Patients and method In this randomized, case-control study, out of 60 patients with atopic dermatitis (age ranging 2 to 45 years), 30 (case) were treated with tacrolimus (0.03%) ointment twice daily and 30 (control) were treated with vaseline twice daily for up to 3 weeks. Evaluation included per cent body durface area (%BSA) affected, individual signs of atopic dermatitis, the Severity Score of Atopic dermatitis (SCORAD), and the patient’s assessment of pruritus.Result The outcome variables like erythema, edema/papulation, oozing/crusting, excoriation, pruritus, body surface area involved and SCORAD in the case group improved significantly compared to those in the control group (p< 0.001, <0.001, <0.001, <0.005, <0.001, <0.001 and <0.001, respectively). After 3 weeks of tacrolimus, all variables except lichenification score responded significantly. Significantly higher number complained of burning sensation in cases (20%) as compared to none in the control group.Conclusion Topical 0.03% tacrolimus is more effective than the vehicle alone.References
Leung DYM, Sorter NA. Cellular and immunological mechanisms in atopic dermatitis. J Am Acad Dermatol 2001; 44 (1 Suppl): S1-12.
Rudikoff D, Lebwohi M. Atopic dermatitis. Lancet 1998; 351: 1715-21.
Schultz-Larsen F, Holm NV, Hennigsen K. Atopic dermatitis. A genetic-epidemiological study in a population base twin sample. J Am Acad Dermatol 1986; 15: 487-94.
Williams HC. Epidemiology of atopic dermatitis. Clin Epidemiol Dermatol 2000; 25: 522-9.
Drake L, Prendergast M, Maher R et al. The impact of tacrolimus ointment on health related quality of life of adult and pediatrc patient with atopic dermatitis. J Acad Dermatol 2001; 44 (1 Suppl): S65-72.
Finlay AY. Quality of life in atopic dermatitis. J Am Acad Dermatol 2001; 45: 64-6.
Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980; 92: 44-7.
Tofte SJ, Hanifin JM. Current management and therapy of atopic dermatitis. J Am Acad Dermatol 2001; 44 (1 Suppl): S13-6.
Leung DYM, Eichenfield LF, Boguniewicz M. Atopic dermatitis. In: FreedbergIM, Eisen AZ, Wolff K et al editors. Fitzpatrick’s Dermatology in General Medicine, 6th edn. New York: Mc-Graw Hill; 2003. p. 1180-94
Lin AN. Topical immunotherapy. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. New York: WB Saunders; 2001. p. 616-29.
Kino T, Hatanaka H, Hasitomo M et al. FK-506A novel immunosuppressant isolated from a streptomyces. J Antibiotics 1987; 40: 1249-55.
Ruzicka T. Atopic eczema between rationality and irrationality. Arch Dermatol 1998; 134: 1462-9.
De Rie MA, Meinardi MM, Bos JD. Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis. Acta Derm Venerreol 1991; 71: 452-4.
Reitamo S, Rustin M, Razika T et al. Efficacy and safety of tacrolimus ointment compared to that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 547-55.
Reitamo S, Rissanen J, Remitz A et al. Tacrolimas ointment does not affect collagen synthesis: results of single- centered randomized trial. J Invest Dermatol 1998; 111: 396-8.
Hanifin JM, Ling MR, Langley R et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol 2001; 44 (1 Suppl): S28-38.
Paller A, Eichenfield LF, Leung DYM et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44 (1 Suppl): S47-57.
Ruzicka T, Bieber T, Schopf E et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997 18; 337: 816-21.
Nakagawa H, Etoh T, Ishibashi Y et al. Tacrolimus ointment for atopic dermatitis. Lancet 1994; 344: 883.
Boguniewicz M, Fiedler VC, Raimer S et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998; 102: 637-44.
Alaiti S, Kang S, Fiedler VC et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol 1998; 38: 69-76.
Kang S, Lucky AW, Pariser D et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44 (1 Suppl): S58-64.
Soter NA, Fleischer AB,Webster GF et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol 2001; 44 (1 Suppl): S39-46.
Reitamo S, Wollenberg A, Schopf E et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000; 136: 999-1006.
Reitamo S, Van Leent EJM, Ho V et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 539-46.
